Leading Pan-European Nurses Association (EDTNA) accredits Sanofi Patient Education Game


Paris, France (October 20, 2014) – The accreditation committee of the European Dialysis and Transplant Nurses Association/European Renal Care Association (EDTNA/ERCA) approved the patient education tool called “Phosphorus Mission”, granting it a three-year accreditation status. EDTNA/ERCA describes “Phosphorus Mission” as an “excellent resource for the nephrology nurse” and “very good teaching and learning aid for patients” in its accreditation letter. 

The committee highlighted a number of evaluation criteria for “Phosphorus Mission”, including inter-activity, judging it as “highly interactive and engaging and could be used by all age groups including patients, carers and extended family”, and  it recommended the mobile application also as a “supplement in patient education groups”. Other elements that counted favorably for the assessors included the fact that the tool is based on a user-friendly technology combining a gaming concept, a fun activity, with a serious message.


“Phosphorus Mission” is available in a number of countries including France, Sweden, Singapore, Philippines, Korea, Malaysia, Russia, Kazakhstan, South Africa, and India, with more to come. To meet patients’ needs around the world, the app was customized to integrate a broad variety of dietary habits including those in Asia, India and the Middle East.


To learn more or download the app, search for “Phosphorus Mission” on your usual Apple® store app or Google Play™ store app. 


The accreditation certificate was handed to Sanofi at the EDTNA/ERCA congress in Riga in September 2014.





Phosphorus Mission

This education tool is approved by the European Dialysis and Transplant Nurses Association/European Renal Care Association. 




“Phosphorus Mission” is a patient education programme that comes as a mobile application designed and developed by Sanofi together with patients and caregivers for people with advanced chronic kidney disease. Educational and entertaining, the programme aims at helping patients better understand chronic kidney disease, treatment options, and dietary choices.


The input gathered from patients and healthcare professionals throughout all stages of the development of this patient education programme– from concept, to development, testing and launch – has contributed to the acceptance the programme has achieved today, which includes the accreditation through the nurses associations EDTNA/ERCA. “Phosphorus Mission” explains to a patient how one may better handle situations which are complex, such as a dialysis, helping the patient understand the role of minerals, consumed with the daily nutrition, on overall clinical condition and therapy. “Phosphorus Mission” is designed to enable patients to assimilate essential information on chronic kidney disease, the impact of food choices, as well as the role of prescribed treatments.



 An innovative tool

“Phosphorus Mission” was presented for the first time in September 2013 in Sweden at the conference of the European Dialysis and Transplant Nurses Association (EDTNA), an organization of nurses and nursing dialysis specialists. As an innovative e-health tool, “Phosphorus Mission” is considered to respond to an unmet need in the treatment of dialysis patients. Already available in the Philippines, Singapore, Malaysia, South Africa and France (Mission Phosphore), the game can be downloaded for use on both tablets and smartphones.



Mission-Based Gaming – How does it work?

As a dialysis patient engages in a “mission”, the patient is then informed on the amount of certain ingredients (phosphorus) contained in his meal and that he might no longer eliminate due to kidney failure. He is then invited to engage in a gameplay where he can target and eliminate excess minerals before they hazardously build-up in his body. To gain bonuses, the player is submitted to a quiz covering information critical in the management of the disease. The gameplay includes 16 levels of escalating difficulty engrained with an escalating level of phosphorus-rich food. As the patient continues to play, he can gain knowledge of potentially dangerous minerals contained in excess in daily meals, which may help the person adopt healthier dietary choices. In addition, the tool provides support for a compliant attitude towards prescribed medications. “Phosphorus Mission” also includes libraries with information (salt, potassium, proteins and more) for users who want to learn without gaming.


The app “Phosphorus Mission” may be available for download in application stores depending on the local regulations. Please check if it is available in your country. For any information related to your health condition, please consult your Healthcare Professional.   



About Chronic Kidney Disease

The bodies’ kidneys are two bean-shaped organs, each about the size of a fist. They are located near the middle of the back, just below the rib cage. Inside each kidney, about a million tiny structures called nephrons filter blood. They remove waste products and extra water, which becomes the urine.


Damaged kidneys can lose the ability to efficiently clean blood, leading to dangerous buildup of waste products and water in the body. This condition is called Chronic Kidney Disease; it may develop in people living with uncontrolled elevated blood pressure (hypertension) or diabetes (high blood sugar). 


If kidneys fail filtering the blood, an external blood filter, dialysis, may contribute to cleaning the blood from toxic substances and complement or substitute the body’s kidney function. 


An estimated 5% to 10% of the world’s population suffers from chronic kidney disease, while the number of dialysis patients is estimated to amount to one million people.



About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Sanofi, 20.10.2014 (tB).


Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds


Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern


„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…


Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen


WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege


Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen


Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…